Formulation Development
Halda Therapeutics Receives FDA Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer Treatment
Halda Therapeutics recently announced the US FDA granted Fast Track designation to HLD-0915, the company’s lead development candidate, for the treatment of patients with metastatic…
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
Tiziana Life Sciences, Ltd. recently announced the first participant has been enrolled and dosed in its Phase 2a clinical trial evaluating intranasal foralumab in patients…
Fifty 1 Labs & The Gates Foundation Lead Largest-Ever Sickle Cell Disease Study
Fifty1 AI Labs, Inc. recently announced the completion of the largest and most comprehensive study of Sickle Cell Disease (SCD) ever undertaken. Leveraging a decade's worth…
Superluminal Medicines Announces Collaboration With Eli Lilly to Advance Small Molecule Therapeutics for Cardiometabolic Diseases & Obesity
Superluminal Medicines recently announced a collaboration with Eli Lilly and Company to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and…
Colorcon Ventures Invests in Phytolon to Advance the Future of Natural Colorants
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in Phytolon, a startup company offering natural food coloring via precision fermentation of modified…
ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules
In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products.
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+ for Cancer
BriaCell Therapeutics Corp. recently announced its acceptance into Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator 2025 Cohort program. This project aims to accelerate the…
MAIA Biotechnology Granted Patent for Next-Generation Telomere-Targeting Agents for Cancer Therapy
MAIA Biotechnology, Inc. recently announced the European Patent Office has decided to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer…
NodThera Demonstrates Reversal of Neuroinflammation & Inflammation in Parkinson’s Disease With Oral NLRP3 Inhibitor
NodThera recently announced the full publication of positive data from its Parkinson’s disease Phase 1b/2a study evaluating the effects of NT-0796, its oral, brain-penetrant NLRP3…
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
AAVantgarde Bio recently announced the US FDA has granted Fast Track Designation for AAVB-039, the company’s gene therapy program for Stargardt disease secondary to biallelic…
Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for Registrational Trial of AXPAXLI in NPDR
Ocular Therapeutix, Inc. recently announced it has received written agreement regarding a registrational trial design from the US FDA under a Special Protocol Assessment (SPA)…
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination & Effective Maintenance Following Discontinuation of GLP-1RA Therapy
Aardvark Therapeutics, Inc. recently announced new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity and obesity-related conditions. Data in…
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances With a Potential to Realize the Full Promise of KRAS & PI3K Inhibition
BridgeBio Oncology Therapeutics, Inc. (BBOT) recently announced the closing of its previously announced business combination with Helix Acquisition Corp. II (formerly Nasdaq: HLXB) (Helix), a…
FDA Approves Tiziana Life Sciences' Phase 2 IND for Multiple System Atrophy
Tiziana Life Sciences, Ltd. recently announce the US FDA has approved the IND for its Phase 2a clinical trial of intranasal foralumab in patients with…
Sever Pharma Solutions Expands Partnership With Silo Pharma on Novel Ketamine-Based Implant for Chronic Pain & Fibromyalgia
Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled-release systems for high potent drugs, recently announced an expanded agreement with…
FoRx Therapeutics Initiates First-in-Human Trial With Novel Anti-Cancer Drug Targeting DNA Damage Response
FoRx Therapeutics recently announced the dosing of the first patient in a first-in-human clinical study of FORX-428, a novel PARG inhibitor designed to target and…
GT Biopharma Advances Into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
GT Biopharma, Inc. recently announced initiation of dosing in Cohort 3 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or…
Legend Biotech Reports Recent Highlights & Second Quarter Results
Legend Biotech Corporation recently reported its second quarter 2025 unaudited financial results and key corporate highlights. “The groundbreaking 5-year survival data from CARTITUDE-1, with one-third…
Nanexa Signs Continuation of Feasibility Agreement With Major Pharmaceutical Company to Investigate PharmaShell Long-Acting Formulations in a Multi-Billion US Market
Nanexa has recently announced the signing of an extension of a feasibility agreement with a major pharmaceutical company to investigate the use of Nanexa´s proprietary…
Assembly Biosciences Reports Positive Interim Results From Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate Showing Reductions in Viral Shedding Rate & Genital Lesion Rate in Recurrent Genital Herpes
Assembly Biosciences, Inc. recently announced positive interim antiviral activity, clinical outcomes, safety, and pharmacokinetic (PK) results from a Phase 1b study evaluating ABI-5366, an investigational…
